{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:52:22Z","timestamp":1790628742233,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Resistance to the currently available treatment paradigms is one of the main factors that contributes to poor outcomes in patients with advanced cervical cancer. Novel targeted therapy approaches might enhance the patient\u2019s treatment outcome and are urgently needed for this malignancy. While chimeric-antigen receptor (CAR)-based adoptive immunotherapy displays a promising treatment strategy for liquid cancers, their use against cervical cancer is largely unexplored. This study used alpharetroviral SIN vectors to equip natural killer (NK) cells with a third-generation CAR (including CD28 and 4-1BB co-stimulatory domains) targeting Mesothelin, which was identified to be highly expressed on primary human cervical cancer tissues and cervical cancer cell lines in this and other studies. Anti-Mesothelin CAR-NK cells demonstrated high cytotoxicity against cervical cancer cells in 2D and 3D culture models, which corresponded to increased degranulation of CAR-NK-92 cells upon exposure to Mesothelin\n                    <jats:sup>+<\/jats:sup>\n                    target cells. Mesothelin\n                    <jats:sup>-<\/jats:sup>\n                    cervical cancer cells were generated by CRISPR-Cas9-mediated knockout and used to show target antigen specificity of anti-Mesothelin CAR-NK-92 cells and primary NK cells derived from different healthy donors in co-culture experiments. Combination of anti-Mesothelin CAR-NK-92 cells with chemotherapy revealed increased elimination of cancer cells as compared to monotherapy settings. Our findings indicate the promise of anti-Mesothelin CAR-NK cells as a potential treatment option against cervical cancer, as well as other Mesothelin\n                    <jats:sup>+<\/jats:sup>\n                    malignancies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1485461","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:12:39Z","timestamp":1734307959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Ivana","family":"Kutle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Polten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Lennart","family":"Stalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hachenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Todzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Hass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"von der Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"von Kaisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schaudien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Seyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Klapdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Alexander","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1105265","article-title":"T cell immunotherapy for cervical cancer: challenges and opportunities","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-018-4933-z","article-title":"Mesothelin as a target for cervical cancer therapy","volume":"299","author":"J\u00f6hrens","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/mcbr.2000.0181","article-title":"Structure of the mesothelin\/MPF gene and characterization of its promoter","volume":"3","author":"Urwin","year":"2000","journal-title":"Mol Cell Biol Res Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-024-05174-y","article-title":"Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer","volume":"22","author":"Guo","year":"2024","journal-title":"J Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"7","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discovery"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers15051357","article-title":"Challenges of anti-mesothelin CAR-T-cell therapy","volume":"15","author":"Zhai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library","volume":"14","author":"Vaughan","year":"1996","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/v6124811","article-title":"Alpharetroviral vectors: From a cancer-causing agent to a useful tool for human gene therapy","volume":"6","author":"Suerth","year":"2014","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00182-10","article-title":"Self-inactivating alpharetroviral vectors with a split-packaging design","volume":"84","author":"Suerth","year":"2010","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0042","article-title":"Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates","volume":"100","author":"Sandrin","year":"2002","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymthe.2005.08.012","article-title":"Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine\u2013DNA methyltransferase in hematopoietic cells","volume":"13","author":"Schambach","year":"2006","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.01.057","article-title":"All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase","volume":"35","author":"Maetzig","year":"2014","journal-title":"Biomaterials"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0126-4","article-title":"In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model","volume":"9","author":"Otte","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0215-4","article-title":"Enhanced metastatic capacity of breast cancer cells after interaction and hybrid formation with mesenchymal stroma\/stem cells (MSC)","volume":"16","author":"Melzer","year":"2018","journal-title":"Cell Commun Signal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/gt.2017.20","article-title":"Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells","volume":"24","author":"Hoffmann","year":"2017","journal-title":"Gene Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.11.014","article-title":"Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group","volume":"45","author":"de Foucher","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.984896","article-title":"Immune checkpoint inhibitors in cervical cancer: Current status and research progress","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.756029","article-title":"Cell therapy: types, regulation, and clinical benefits","volume":"8","author":"El-Kadiry","year":"2021","journal-title":"Front Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-4007","article-title":"Abstract 4007: AIC100 CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of non-small cell lung cancer (NSCLC) and cervical cancer (CC)","volume":"84","author":"Birt","year":"2024","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091296","article-title":"Generation and functional characterization of PLAP CAR-T cells against cervical cancer cells","volume":"12","author":"Yekehfallah","year":"2022","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05734-9","article-title":"Favorable therapeutic response after anti-Mesothelin antibody\u2013drug conjugate treatment requires high expression of Mesothelin in tumor cells","volume":"302","author":"Lazzerini","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.7015","article-title":"Mesothelin\u2212targeted second generation CAR\u2212T cells inhibit growth of mesothelin\u2212expressing tumors in vivo","volume":"17","author":"Ye","year":"2018","journal-title":"Exp Ther Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science (80-)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082323","article-title":"The function of NK cells in tumor metastasis and NK cell-based immunotherapy","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123225","article-title":"Enhancement of the anticancer ability of natural killer cells through allogeneic mitochondrial transfer","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6342","article-title":"Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer","volume":"16","author":"Sun","year":"2018","journal-title":"Exp Ther Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910595","article-title":"Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies","volume":"13","author":"Seliger","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/hum.2009.122","article-title":"4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell Malignancies","volume":"21","author":"Tammana","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3Z\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discovery"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4230","article-title":"Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity","volume":"169","author":"Wilcox","year":"2002","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12885-015-1321-y","article-title":"Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids","volume":"15","author":"Giannattasio","year":"2015","journal-title":"BMC Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01133","article-title":"High-throughput microfluidic 3D cytotoxicity assay for cancer immunotherapy (CACI-IMPACT platform)","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.32604\/Oncologie.2021.015969","article-title":"Growth and invasion of 3D spheroid tumor of HeLa and CasKi cervical cancer cells","volume":"23","author":"Muniandy","year":"2021","journal-title":"Oncologie"},{"key":"B64","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am J Transl Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.05.005","article-title":"Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors","volume":"154","author":"Maru","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030694","article-title":"Establishment and molecular phenotyping of organoids from the squamocolumnar junction region of the uterine cervix","volume":"12","author":"Maru","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e35","article-title":"Preclinical investigation of patient-derived cervical cancer organoids for precision medicine","volume":"34","author":"Seol","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.stem.2021.03.012","article-title":"Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer","volume":"28","author":"L\u00f5hmussaar","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1111\/cas.14119","article-title":"Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma","volume":"110","author":"Maru","year":"2019","journal-title":"Cancer Sci"},{"key":"B70","unstructured":"FDA investigating serious risk of T-cell Malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies\n          \n          \n          \n          2023"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024166","article-title":"Second primary Malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS)","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/genes5020415","article-title":"Genome-wide analysis of alpharetroviral integration in human hematopoietic stem\/progenitor cells","volume":"5","author":"Moiani","year":"2014","journal-title":"Genes (Basel)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.309","article-title":"Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity","volume":"20","author":"Suerth","year":"2012","journal-title":"Mol Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01194","article-title":"Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance","volume":"8","author":"Zingoni","year":"2017","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR\u2013dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201426","article-title":"Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell\u2013mediated cytotoxicity in multiple myeloma cells: role of STAT3","volume":"190","author":"Fionda","year":"2013","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.830570","article-title":"MSLN correlates with immune infiltration and chemoresistance as a prognostic biomarker in ovarian cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1571555","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1485461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:34:34Z","timestamp":1740112474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1485461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2024.1485461"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1485461","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1485461"}}